OBJECTIVES: Despite the wide use of Health Technology Assessment (HTA) in some countries, common understanding of value definition and attributes that contribute to value in healthcare is lacking. In response to the debate on access to expensive drugs, various drug value frameworks (VFs) have emerged in recent years. This research aims at comprehensive identification of existing “non-HTA” VFs in the context of this current debate.

METHODS: Comprehensive literature review of Medline and Japanese ICHUSHI database, websites of ESMO, EU Cancer Patient Coalition, OECD, ASCO, NCCN, and other scientific/governmental organisations was conducted with no time restrictions up to April, 2017 year to identify VFs others than used by HTA agencies. A descriptive analysis was performed to characterise VFs and trends in their development.

RESULTS: CONCLUSIONS: VFs others than those used by HTA agencies are gaining importance but their current impact on decision-making is minor. More practicability and validity are expected to enhance their wider adoption. HTA agencies in Europe are showing increased interest in such VFs, which may end up more influential in Europe than in the US.